Chart-Typ:
Zeitraum:
| ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy | - Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA - MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics... ► Artikel lesen |
| ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy | - ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders - - Topline Data Expected Mid-Year 2025 - MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) --... ► Artikel lesen |
| ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy | - Clinically Meaningful Benefit Observed at Both ATH434 Doses Studied - - Achieved Statistical Significance with Up to 48% Slowing of Clinical Progression on UMSARS Rating Scale - - Key MRI Biomarker... ► Artikel lesen |
| SurgePays Reports First Quarter 2025 Financial Results | AT&T Integration Complete; Nationwide Launch Positions Company for Most Aggressive Growth Phase to Date
Company Ships Over 250,000 SIM Cards and Secures $6 Million... ► Artikel lesen |
| Pre-market Movers: OSR Holdings, SurgePays, Beeline Holdings, Humacyte, Tenon Medical | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.45 A.M. ET).In the Green OSR Holdings, Inc. (OSRH) is up over 173% at $4.37.
SurgePays... ► Artikel lesen |
| SurgePays Reports 2024 Financial Results and Issues Revenue Guidance of Over $200 Million in Next 12 Months | Completed AT&T integration positions company for its most aggressive growth phase to date with projected positive cash flow from operations in 2025
BARTLETT, Tenn.... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting | TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels Increase Over Time All Cohort 1 Patients with... ► Artikel lesen |
| Tenaya Therapeutics, Inc.: Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models | SOUTH SAN FRANCISCO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.